The Effect of a Probiotic on Hepatic Steatosis

Solga, Steven F.; Buckley, Gillian J.; Clark, Jeanne M.; Horská, Alena; Diehl, Anna Mae

doi:10.1097/mcg.0b013e31816d920c

Cited by 48 publications

(31 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three RCTs assessed probiotics in NAFLD: the first, evaluating VSL3, was prematurely terminated for an increase in hepatic steatosis [103]; the others, assessing a mixture of Lactobacillus spp. plus either Bifidobacterium bifidum or Streptococcus thermophilus, found a significant improvement in MRS-assessed hepatic fat and aminotransferases, respectively [104,105].…”

Section: %) (G) Homa Index Change (%) (H) Fpg Change (%) (I) Serummentioning

confidence: 99%

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

et al. 2012

View full text Add to dashboard Cite

Aims/hypothesis Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH): NAFLD causes an increased risk of cardiovascular disease, diabetes and liverrelated complications (the latter confined to NASH). The effect of proposed treatments on liver disease, glucose metabolism and cardiovascular risk in NAFLD is unknown. We reviewed the evidence for the management of liver disease and cardiometabolic risk in NAFLD. Methods Publications through November 2011 were systematically reviewed by two authors. Outcomes evaluated though standard methods were: histological/radiological/biochemical features of NAFLD, variables of glucose metabolism and cardiovascular risk factors. Seventy-eight randomised trials were included (38 in NASH, 40 in NAFLD): 41% assessed post-treatment histology, 71% assessed glucose metabolism and 88% assessed cardiovascular risk factors. Lifestyle intervention, thiazolidinediones, metformin and antioxidants were most extensively evaluated. Results Lifestyle-induced weight loss was safe and improved cardio-metabolic risk profile; a weight loss ≥7% improved histological disease activity, but was achieved by <50%

show abstract

Section: %) (G) Homa Index Change (%) (H) Fpg Change (%) (I) Serummentioning

confidence: 99%

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the clinical efficacy of probiotics still needs further validation in well-designed studies with larger scale of participants because of the some discrepant results among different studies. For instance, Solga et al hypothesized that probiotics would reduce hepatic steatosis in humans [110]. However, at the end of 4 months, all 4 subjects behaved a significant increase in liver fat, which indicated the opposite trend compared with the initial assumptions.…”

Section: Gut Microbiota-targeted Therapies Of Nafldmentioning

confidence: 75%

“…22 patients with NAFLD + 20 patients with AC [169] Experiencing a significant increase in liver fat ; no significant differences in any of 4 patients with NAFLD [110] the blood assays or clinical parameters…”

Section: Lactobacillus (Lcs)mentioning

confidence: 99%

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Ma¹,

Zhou²,

Li³

2017

Preprint

View full text Add to dashboard Cite

Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first described the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies in NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiotatargeted therapies in the future.

show abstract

“…Several proand prebiotics, such as VSL+3, MIYAIRI588, Bifidobacterium bifidum, and Lactobacillus plantarum, and antibiotics may have beneficial effects (143)(144)(145)(146)(147). Nonetheless, conflicting data on VSL+3 suggesting a detrimental effect on hepatic steatosis raise questions about interindividual differences in response to probiotics (148). Despite some evidence in other gastrointestinal and nongastrointestinal diseases, modulation of gut microbiota by fecal transplantation has not been studied in liver disease so far except for a very recent pilot study in AH showing that transplantation was associated with increased 1-year survival rates (149).…”

Section: Different Underlying Pathophysiologies and Therapeutic Implimentioning

confidence: 91%

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis

et al. 2017

View full text Add to dashboard Cite

The Effect of a Probiotic on Hepatic Steatosis

Cited by 48 publications

References 10 publications

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis

Contact Info

Product

Resources

About